ST-1891

ST-1891 is a novel, oral investigational product for the treatment of hypothyroidism.

ST-1891 has been tested in 4 completed Phase 1 clinical studies in healthy adult volunteers.

Sention is conducting a multicenter, randomized, Phase 2 clinical study of ST‑1891 in patients with hypothyroidism (NCT05412979).